112 related articles for article (PubMed ID: 21506898)
21. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.
Karlstad O; Starup-Linde J; Vestergaard P; Hjellvik V; Bazelier MT; Schmidt MK; Andersen M; Auvinen A; Haukka J; Furu K; de Vries F; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):333-48. PubMed ID: 24215311
[TBL] [Abstract][Full Text] [Related]
22. Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2012 Mar; 51(3):400-2. PubMed ID: 22497435
[No Abstract] [Full Text] [Related]
23. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
24. Insulin glargine and malignancy: an unwarranted alarm.
Pocock SJ; Smeeth L
Lancet; 2009 Aug; 374(9689):511-3. PubMed ID: 19616841
[No Abstract] [Full Text] [Related]
25. Cancer occurrence in Danish diabetic patients: duration and insulin effects.
Carstensen B; Witte DR; Friis S
Diabetologia; 2012 Apr; 55(4):948-58. PubMed ID: 22120574
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine and risk of cancer: a meta-analysis.
Du X; Zhang R; Xue Y; Li D; Cai J; Zhou S; Huang Z; Yu R; Liu Y
Int J Biol Markers; 2012 Oct; 27(3):e241-6. PubMed ID: 22865296
[TBL] [Abstract][Full Text] [Related]
27. Insulin glargine controversy: a tribute to the editorial team at Diabetologia.
Butler PC
Diabetes; 2009 Nov; 58(11):2427-8. PubMed ID: 19875618
[No Abstract] [Full Text] [Related]
28. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
29. Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study.
Borgquist S; Rosendahl AH; Czene K; Bhoo-Pathy N; Dorkhan M; Hall P; Brand JS
Breast Cancer Res; 2018 Aug; 20(1):93. PubMed ID: 30092829
[TBL] [Abstract][Full Text] [Related]
30. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
31. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.
Wu JW; Filion KB; Azoulay L; Doll MK; Suissa S
Diabetes Care; 2016 Mar; 39(3):486-94. PubMed ID: 26740633
[TBL] [Abstract][Full Text] [Related]
32. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
33. Insulin glargine and cancer--an unsubstantiated allegation.
Garg SK; Hirsch IB; Skyler JS
Diabetes Technol Ther; 2009 Aug; 11(8):473-6. PubMed ID: 19591544
[No Abstract] [Full Text] [Related]
34. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
35. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
36. [Increased risk of cancer using insulin and insulin analogues?].
Schäffler A
MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
[No Abstract] [Full Text] [Related]
37. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
38. Insulin glargine and its role in glycaemic management of Type 2 diabetes.
Elrishi MA; Jarvis J; Khunti K; Davies MJ
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1099-110. PubMed ID: 18680444
[TBL] [Abstract][Full Text] [Related]
39. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
